Uterine Cancer Clinical Trials 2024

What are the top hospitals conducting uterine cancer research?

Uterine cancer, a condition affecting the uterus or womb, is an area of focus for several leading hospitals conducting groundbreaking clinical trials. In New york City, Memorial Sloan Kettering Cancer Center leads the way with four active uterine cancer trials and a total of 14 trials dedicated to this specific type of cancer since their first recorded trial in 2000. Across the country in Durham, Duke University Medical Center is making significant contributions as well. With two ongoing uterine cancer trials and a history of five completed studies dating back to their initial trial in 2006.

In Vancouver, Northwest Cancer Specialists, P.C., has emerged as a key player in uterine cancer research. Though relatively new to this field with just two active trials at present and only two recorded trials overall since their inaugural investigation commenced recently in 2021. Similarly situated hospital that began studying on Uteriane cases primarily from early last year is HonorHealth based out Phoenix; they share similar statistics with dual current investigations being held along with same number historical data reflects upon them.

Notably adding itself to this list is Northwestern University located within Chicago's medical landscape where there are presently multiple investigations conducted simultaneously focusing on Uterian conditions while contributing towards expanding knowledge base through undertaking about five such experiments previously ever since commencing its pioneering investigation around2015.

These distinguished healthcare institutions signify not only progress but also hope for those impacted by uterine cancer across the nation and beyond. Through these clinical trials, researchers aim to uncover new treatment options and strategies that could ultimately improve outcomes for patients facing this challenging disease.

Which are the best cities for uterine cancer clinical trials?

When it comes to uterine cancer clinical trials, several cities have emerged as leaders in research and development. New york City, with its 10 active trials, investigates promising treatments like trastuzumab, ACR-368, and Seribantumab. Anchorage in Alaska follows closely behind with 9 ongoing studies focusing on Subprotocol C2 (MET exon 14 deletion/mutation) and ACR-368 among others. Phoenix, Arizona also offers significant opportunities for participation in clinical trials with 6 ongoing studies exploring trastuzumab and Subprotocol C2 (MET exon 14 deletion/mutation). These cities provide individuals fighting uterine cancer access to cutting-edge clinical trials that pave the way for advancements in care and offer hope for improved outcomes.

Which are the top treatments for uterine cancer being explored in clinical trials?

Exciting developments are underway in clinical trials exploring treatments for uterine cancer. Leading the charge is trastuzumab, with one active trial and a total of one all-time uterine cancer trial since its introduction in 2021. Another promising contender is seribantumab, currently involved in one ongoing uterine cancer study after being listed in 2020. Intraperitoneal chemotherapy has also attracted attention with one active and all-time uterine cancer trial, first appearing on the scene in 2020. Last but not least, AZD1775 joins the lineup as an intriguing treatment option that debuted back in 2018 and continues to be tested extensively through one active and all-time uterine cancer trials. These groundbreaking efforts offer hope for improved outcomes for patients battling this challenging disease.

What are the most recent clinical trials for uterine cancer?

Recent clinical trials for uterine cancer offer promising advancements in treatment options. One notable study focuses on the ovarian cancer arm, which investigates the effectiveness of certain therapies for uterine cancer patients. Another trial targets recurrent or metastatic uterine cancer to explore potential interventions tailored specifically for this challenging stage. Additionally, a Phase 1 and Phase 2 trial examines the combination of Cabo and Dostarlimab as a potential treatment option for uterine cancer. Furthermore, Part C of a multi-phase trial explores expansion cohorts studying SNS-101 alone or in combination with cemiplimab in an effort to expand therapeutic choices available to patients with uterine cancer. Lastly, another Phase 2 trial evaluates the efficacy of combining eribulin and pembrolizumab to enhance outcomes for individuals battling this form of cancer.

What uterine cancer clinical trials were recently completed?

A recent milestone in the field of uterine cancer research was achieved with the completion of a clinical trial for Atezolizumab. Sponsored by Gradalis, Inc., this trial concluded in May 2017. Although further updates on recently completed trials are not available at this time, ongoing efforts continue to explore new avenues and potential treatments for uterine cancer. The findings from completed studies like the Atezolizumab trial contribute to our understanding of this disease and pave the way for future advancements in its management and treatment.